Popular Articles
Burdock Root

Mycamine(R) Now Available In 13 EU Markets For Treatment Of Serious Fungal Infections
MYCAMINE (micafungin), the newest echinocandin, is now available in thirteen European markets: UK, Greece, Czech Republic, Slovakia, Nordic region*, Spain, Germany, Ireland and France following its EU approval in April 2008.
generic viagra online
Increase In Assisted Reproduction Revealed By Worldwide Report
Assisted reproductive technology (ART) is responsible for an estimated 219,000 to 246,000 babies born each year worldwide according to an international study. The study also finds that the number of ART procedures is growing steadily: in just two years (from 2000 to 2002) ART activity increased by more than 25%.
News of the day
UK Watchdog Calling For Clearer Labelling Compared A Supermarket Salad To A Big Mac
A UK consumer watchdog that is campaiging for clearer food labelling analysed a selection of pre-packed salads from high street supermarkets
Sexual Health

How Superbugs Control Their Lethal Weapons

It appears that some superbugs have evolved to develop the ability to manipulate the immune system to everyone"s advantage. A team of researchers at The University of Western Ontario, led by Joaquin (Quim) Madrenas of the Robarts Research Institute, has discovered some processes that reduce the lethal effects of toxins from superbugs, allowing humans and microbes to co-evolve. This discovery may lead to novel alternatives to antibiotics that specifically target the toxic effects of these superbugs. The findings are being published in the journal Nature Medicine and are available online today. Madrenas holds a Canada Research Chair in Immunobiology and is a Professor of Microbiology & Immunology, and Medicine at the Schulich School of Medicine & Dentistry at Western. He also is head of Immunology at Robarts Research Institute and Director of the FOCIS Centre for Clinical Immunology and Immunotherapeutics. Staphylococcus (staph) aureus is the leading cause of infections in hospitals and the second most common cause of infections in the general population. By itself, it is linked to more than half a million hospital admissions a year in North America with estimated costs of more than $6 billion per year. Among the many weapons produced by this superbug, the most potent and lethal ones are known as superantigens. These lethal weapons cause massive and harmful activation of the immune system that leads to Toxic Shock Syndrome (TSS). TSS is a very serious disease that carries a high mortality, for which we do not have a specific treatment. Scientists have been puzzled as to why, when the body is directly exposed to the TSS toxins, a human can die within hours whereas individuals may carry toxin-producing staph and not get sick or die. What has the staph bug got that prevents the immune system of the host from being kicked into high gear? Madrenas and his collaborators at Western, Calgary and Chicago have identified the process that allows the bug to stay in the body without causing that massive activation of the immune system. The secret lies in molecules found in the cell wall of staph. These molecules bind to receptors known as TLR2 on immune cells of the host triggering the production of a protein called IL-10, an anti-inflammatory molecule that will prevent TSS. "It is clear that staph superbugs have developed strategies to control the toxicity of its lethal superantigen toxins, thereby preventing TSS. We believe that this is an important mechanism that warrants continued investigation. It also illustrates that evolution may operate not only by competition but also by networking ultimately leading to peaceful co-existence" says Madrenas. Based on these studies, Madrenas and colleagues have developed a computer model that will help predict the outcomes of encounters between staph and a host, and will reveal new aspects of these encounters. The multidisciplinary team led by Madrenas includes David Heinrichs, Ewa Cairns, Mansour Haeryfar, and John McCormick of the Departments of Microbiology and Immunology, and Medicine at The University of Western Ontario, as well as Paul Kubes from the University of Calgary and Gary An from Northwestern University in Chicago. The research was funded by the Canadian Institutes of Health Research and the Kidney Foundation of Canada. Kathy Wallis University of Western Ontario


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):